Works (1)

Updated: July 5th, 2023 15:50

2009 journal article

Toward a molecular equivalent dose: Use of the medaka model in comparative risk assessment

Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 149(2), 141–151.

By: K. Hobbie n, A. DeAngelo*, L. King*, R. Winn* & J. Law n

author keywords: Risk assessment; Dose-response; DNA; Medaka; cll; Mutation; Adduct; DMN; Nitrosamines
MeSH headings : Animals; Animals, Genetically Modified; Carcinogens / metabolism; Carcinogens / pharmacology; Carcinogens / toxicity; DNA / genetics; DNA / isolation & purification; DNA Adducts / analysis; DNA Adducts / metabolism; Dimethylnitrosamine / metabolism; Dimethylnitrosamine / pharmacology; Dimethylnitrosamine / toxicity; Dose-Response Relationship, Drug; Guanine / analogs & derivatives; Guanine / analysis; Guanine / metabolism; Immunohistochemistry; Liver / drug effects; Liver / metabolism; Liver / pathology; Male; Models, Biological; Mutagenicity Tests; Mutation; Oryzias / genetics; Random Allocation; Rats; Rats, Inbred F344; Rats, Transgenic; Risk Assessment; Water Supply
TL;DR: While liver DNA adduct concentrations were similar in magnitude, mutant frequencies in the DMN-exposed medaka were up to 20 times higher than in the Big Blue rats, and future work with other compounds will generate a more complete picture of comparative dose response between different phyletic levels and will help guide risk assessors using "Alternative" models. (via Semantic Scholar)
UN Sustainable Development Goal Categories
Sources: Web Of Science, Crossref
Added: August 6, 2018

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.